Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
BNF presentation directory
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Ergocalciferol 900units/5ml oral liquid
0906040N0AAEGEG
|
Ergocalciferol | Ergocalciferol | Nutrition and Blood | No data available |
|
Ergometrine 500microgram tablets
0701010L0AAACAC
|
Ergometrine mal | Ergometrine maleate | Obstetrics, Gynaecology and Urinary-Tract Disorders | No data available |
|
Ergometrine 500micrograms/1ml / Oxytocin 5units/1ml inj amp
0701010T0AAAFAF
|
Oxytocin | Oxytocin | Obstetrics, Gynaecology and Urinary-Tract Disorders | No data available |
|
Ergometrine 500micrograms/1ml inj ampoules
0701010L0AAAAAA
|
Ergometrine mal | Ergometrine maleate | Obstetrics, Gynaecology and Urinary-Tract Disorders | No data available |
|
Ergoral D2 5,000unit tablets
0906040N0BYABAP
|
Ergoral D2 | Ergocalciferol | Nutrition and Blood | No data available |
|
Ergoral D2 50,000unit capsules
0906040N0BYADFL
|
Ergoral D2 | Ergocalciferol | Nutrition and Blood | No data available |
|
Ergoral D2 500unit tablets
0906040N0BYAAEW
|
Ergoral D2 | Ergocalciferol | Nutrition and Blood | No data available |
|
Ergotamine tartrate 2mg / Caffeine 100mg suppositories
0407041F0AAAHAH
|
Ergotamine tartrate | Ergotamine tartrate | Central Nervous System | No data available |
|
Eribulin 1320micrograms/3ml solution for injection vials
0801050BBAAABAB
|
Eribulin | Eribulin | Malignant Disease and Immunosuppression | No data available |
|
Eribulin 880micrograms/2ml solution for injection vials
0801050BBAAAAAA
|
Eribulin | Eribulin | Malignant Disease and Immunosuppression | No data available |
|
Erivedge 150mg capsules
0801050BMBBAAAA
|
Erivedge | Vismodegib | Malignant Disease and Immunosuppression | No data available |
|
Erleada 240mg tablets
0803042V0BBABAB
|
Erleada | Apalutamide | Malignant Disease and Immunosuppression | No data available |
|
Erleada 60mg tablets
0803042V0BBAAAA
|
Erleada | Apalutamide | Malignant Disease and Immunosuppression | No data available |
|
Erlibelle 30microgram/150microgram tablets
0703010F0CDAAAC
|
Erlibelle | Combined ethinylestradiol 30mcg | Obstetrics, Gynaecology and Urinary-Tract Disorders | No data available |
|
Erlotinib 100mg tablets
0801050AEAAAAAA
|
Erlotinib | Erlotinib | Malignant Disease and Immunosuppression | No data available |
|
Erlotinib 150mg tablets
0801050AEAAABAB
|
Erlotinib | Erlotinib | Malignant Disease and Immunosuppression | No data available |
|
Erlotinib 25mg tablets
0801050AEAAACAC
|
Erlotinib | Erlotinib | Malignant Disease and Immunosuppression | No data available |
|
Ervevax vacc inj 0.5ml vials
1404000P0BCAAAE
|
Ervevax | Rubella | Immunological Products and Vaccines | No data available |
|
Erwinase 10,000unit powder for solution for injection vials
0801050J0BBAAAA
|
Erwinase | Crisantaspase | Malignant Disease and Immunosuppression | No data available |
|
Eryacne 2 gel
1306010I0BEAAAD
|
Eryacne | Erythromycin | Skin | No data available |
|
Eryacne 4 gel
1306010I0BEABAE
|
Eryacne | Erythromycin | Skin | No data available |
|
Erythrocin IV lactobionate 1g inf vials
0501050K0BBAAAA
|
Erythrocin (Parenteral) | Erythromycin lactobionate | Infections | No data available |
|
Erythrolar 250mg tablets
0501050N0BCAAAA
|
Erythrolar (Tablet) | Erythromycin stearate | Infections | No data available |
|
Erythrolar 500mg tablets
0501050N0BCABAB
|
Erythrolar (Tablet) | Erythromycin stearate | Infections | No data available |
|
Erythromycin 0.5% Ophthalmic Ointment
1103010I0BCAAAA
|
Erythromycin (Ophthalmic) | Erythromycin | Eye | No data available |
Why monitor BNF codes?
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Understand demand drivers
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.